# Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia

> **NCT02010957** · PHASE3 · TERMINATED · sponsor: **Wuerzburg University Hospital** · enrollment: 85 (actual)

## Conditions studied

- Adrenal Neoplasia

## Interventions

- **OTHER:** FDG positron emission tomography
- **OTHER:** Iodometomidate imaging

## Key facts

- **NCT ID:** NCT02010957
- **Lead sponsor:** Wuerzburg University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2021-01
- **Final completion:** 2022-07
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Stop of tracer production by company, unavailability of 123I Iodometomidate at most study centers, slow recruitment
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02010957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02010957, "Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02010957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*